These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7786769)

  • 1. Low molecular weight heparin(s).
    Barrowcliffe TW
    Br J Haematol; 1995 May; 90(1):1-7. PubMed ID: 7786769
    [No Abstract]   [Full Text] [Related]  

  • 2. Low molecular weight heparin: laboratory properties and clinical evaluation. A review.
    Hirsh J; Levine MN
    Eur J Surg Suppl; 1994; (571):9-22. PubMed ID: 7519092
    [No Abstract]   [Full Text] [Related]  

  • 3. Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent.
    Ofosu FA; Levine M; Craven S; Dewar L; Shafai S; Blajchman MA
    Br J Haematol; 1992 Oct; 82(2):400-5. PubMed ID: 1329920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic activity and its relationship to in vitro anticoagulant effects.
    Gray E; Padilla A; Barrowcliffe TW
    Haemostasis; 1993 Mar; 23 Suppl 1():99-102. PubMed ID: 8388358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
    Leyvraz PF; Bachmann F; Hoek J; Büller HR; Postel M; Samama M; Vandenbroek MD
    BMJ; 1991 Sep; 303(6802):543-8. PubMed ID: 1655136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage.
    Leizorovicz A; Bara L; Samama MM; Haugh MC
    Haemostasis; 1993 Mar; 23 Suppl 1():89-98. PubMed ID: 8388357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management.
    Horlocker TT; Heit JA
    Anesth Analg; 1997 Oct; 85(4):874-85. PubMed ID: 9322474
    [No Abstract]   [Full Text] [Related]  

  • 8. The relationship between ex vivo anti-factor Xa levels and efficacy/safety of low molecular weight heparin.
    Turpie AG
    Br J Clin Pract Suppl; 1989 Jan; 65():18-23; discussion 23-5. PubMed ID: 2554949
    [No Abstract]   [Full Text] [Related]  

  • 9. Strategy for the development of the low molecular weight heparin fraction CY 216 in the prevention of postoperative deep vein thromboses in general surgery.
    Toulemonde F
    Semin Thromb Hemost; 1989 Oct; 15(4):395-400. PubMed ID: 2554500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
    Hirsh J; Dalen JE; Deykin D; Poller L
    Chest; 1992 Oct; 102(4 Suppl):337S-351S. PubMed ID: 1327666
    [No Abstract]   [Full Text] [Related]  

  • 11. LMW heparin: relationship between antithrombotic and anticoagulant effects.
    Barrowcliffe TW
    Adv Exp Med Biol; 1992; 313():205-20. PubMed ID: 1332437
    [No Abstract]   [Full Text] [Related]  

  • 12. [Low molecular weight heparins].
    Doutremepuich C; Lalanne MC; Guyot M; Doutremepuich F; Fernandez G; De Seze O; Deharo E; Vairel EG; Quilichini R
    Ann Pharm Fr; 1989; 47(3):109-16. PubMed ID: 2561387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of venous thromboembolism: unfractionated heparin or low molecular weight heparins?
    Agnelli G
    Haematologica; 1995; 80(2 Suppl):78-83. PubMed ID: 7628776
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-molecular-weight heparin for venous thromboembolism.
    Schafer AI
    Hosp Pract (1995); 1997 Jan; 32(1):99-101, 105-6. PubMed ID: 9006585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
    Boneu B
    Haemostasis; 1996 Oct; 26 Suppl 4():368-78. PubMed ID: 8979141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of deep vein thrombosis--use of the low molecular weight heparin enoxaparin.
    Forbes CD
    Br J Clin Pract; 1989 Nov; 43(11):396-400. PubMed ID: 2558702
    [No Abstract]   [Full Text] [Related]  

  • 17. [The future of low molecular weight heparins in the curative treatment of deep venous thrombosis].
    St-Louis J; St-Louis JM
    Union Med Can; 1994 Mar; 123(3):147-51. PubMed ID: 8184510
    [No Abstract]   [Full Text] [Related]  

  • 18. Low molecular weight heparin.
    Gough S
    BMJ; 1991 Sep; 303(6805):784. PubMed ID: 1657259
    [No Abstract]   [Full Text] [Related]  

  • 19. Prophylactically effective doses of enoxaparin and heparin inhibit prothrombin activation.
    Ofosu FA
    Adv Exp Med Biol; 1992; 313():231-6. PubMed ID: 1332439
    [No Abstract]   [Full Text] [Related]  

  • 20. Thromboprophylaxis with heparin and low molecular weight heparin in elective hip surgery: current status and perspectives.
    Breyer HG
    Semin Thromb Hemost; 1991 Oct; 17(4):336-42. PubMed ID: 1666453
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.